X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ceftazidime-avibactam (240) 240
index medicus (170) 170
microbiology (155) 155
pharmacology & pharmacy (146) 146
infectious diseases (126) 126
enterobacteriaceae (98) 98
humans (97) 97
infections (71) 71
in-vitro activity (70) 70
klebsiella-pneumoniae (68) 68
gram-negative bacteria (67) 67
pseudomonas-aeruginosa (60) 60
anti-bacterial agents - pharmacology (54) 54
anti-bacterial agents - therapeutic use (53) 53
carbapenem-resistant enterobacteriaceae (51) 51
ceftazidime/avibactam (51) 51
antibiotics (50) 50
double-blind (47) 47
ceftazidime (46) 46
escherichia-coli (46) 46
pseudomonas aeruginosa (46) 46
urinary-tract-infections (44) 44
carbapenemase (40) 40
klebsiella pneumoniae (40) 40
microbial sensitivity tests (40) 40
beta-lactamase inhibitor (36) 36
azabicyclo compounds - therapeutic use (35) 35
drug resistance (35) 35
resistance (35) 35
azabicyclo compounds - pharmacology (34) 34
combination (34) 34
susceptibility (34) 34
ceftazidime - therapeutic use (33) 33
kpc (33) 33
avibactam (32) 32
ceftolozane-tazobactam (32) 32
colistin (32) 32
bacteria (31) 31
drug resistance in microorganisms (31) 31
immunology (31) 31
mortality (31) 31
antimicrobial resistance (30) 30
complicated intraabdominal infections (28) 28
pneumonia (28) 28
polycyclic compounds (28) 28
biochemical phenomena, metabolism, and nutrition (27) 27
drug resistance, multiple, bacterial (26) 26
epidemiology (26) 26
meropenem (26) 26
gram-negative bacteria - drug effects (25) 25
ventilator-associated pneumonia (25) 25
ceftazidime-avibactam resistance (24) 24
bacteremia (23) 23
beta lactamases (23) 23
blood-stream infections (23) 23
ceftazidime - pharmacology (23) 23
critically-ill patients (23) 23
drug therapy (23) 23
plus metronidazole (23) 23
antimicrobial agents (22) 22
bacterial infections and mycoses (22) 22
beta-lactamase (22) 22
beta-lactamase inhibitors - therapeutic use (21) 21
internal medicine (21) 21
male (21) 21
surveillance (21) 21
cre (20) 20
drug combinations (20) 20
infectious disease (20) 20
us medical-centers (20) 20
β-lactamase (20) 20
antibiotic resistance (19) 19
beta-lactamases (19) 19
female (19) 19
gram-negative bacterial infections - drug therapy (19) 19
klebsiella (19) 19
klebsiella pneumoniae - drug effects (19) 19
safety (19) 19
adult (18) 18
beta-lactamases - metabolism (18) 18
ceftolozane/tazobactam (18) 18
dosage and administration (18) 18
efficacy (18) 18
health aspects (18) 18
middle aged (18) 18
analysis (17) 17
bacterial pneumonia (17) 17
carbapenems (17) 17
enterobacteriaceae - drug effects (17) 17
pseudomonas aeruginosa - drug effects (17) 17
research (17) 17
tazobactam (17) 17
therapy (17) 17
urinary tract infections (17) 17
beta-lactamase inhibitors - pharmacology (16) 16
beta-lactamases - genetics (16) 16
clinical trials (16) 16
gram-negative bacterial infections - microbiology (16) 16
imipenem (16) 16
klebsiella pneumoniae carbapenemase (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 11/2018, Volume 61, Issue 22, pp. 10340 - 10344
Only one FDA-approved beta-lactamase inhibitor has ever been orally available: clavulanic acid, approved in 1984. Avibactam, approved by FDA in 2015, is the... 
CEFTAZIDIME-AVIBACTAM | CHEMISTRY, MEDICINAL | DIAZABICYCLOOCTANES
Journal Article
Revista Espanola de Cirugia Ortopedica y Traumatologia, ISSN 1888-4415, 11/2018, Volume 62, Issue 6, pp. 471 - 473
There are increasingly more patients with prosthetic implants (orthopaedic prostheses, lumbar instruments, osteosynthesis material). In the last decade,... 
Carbapenemase | Arthrodesis | Ceftazidime/avibactam
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2017, Volume 61, Issue 3
Ceftazidime-avibactam is a novel β-lactam/β-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Klebsiella... 
Resistance | Carbapenem-resistant Enterobacteriaceae | Klebsiella pneumoniae carbapenemase | Sequence type 258 | Ceftazidime-avibactam | Klebsiella pneumoniae | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 05/2019, Volume 68, Issue 11, pp. 1823 - 1830
Abstract Background Overcoming β-lactam resistance in pathogens such as Pseudomonas aeruginosa is a major clinical challenge. Rapid molecular diagnostics... 
ceftazidime/avibactam | ceftolozane/tazobactam | Pseudomonas aeruginosa | antimicrobial resistance
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2018, Volume 62, Issue 8
Carbapenem-resistant and hypervirulent (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the activity of... 
Carbapenem resistance | Susceptibility | Ceftazidime-avibactam | Hypervirulent Klebsiella pneumoniae
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2017, Volume 61, Issue 3
Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae isolates have been increasingly reported worldwide, and therapeutic options to treat... 
Ceftazidime-avibactam | Permeability | KPC | Index Medicus
Journal Article
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 12/2016, Volume 63, Issue 12, pp. 1619 - 1621
Journal Article
International journal of antimicrobial agents, 08/2019
BACKGROUNDSeveral clinicians use ceftazidime-avibactam in combination with other active agents to treat infections due to carbapenem-resistant organisms,... 
Index Medicus
Journal Article
Diagnostic Microbiology and Infectious Disease, ISSN 0732-8893, 05/2019
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 12/2016, Volume 63, Issue 12, pp. 1619 - 1621
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 03/2018, Volume 62, Issue 3
Ceftazidime-avibactam (CAZ-AVI) is a promising novel treatment for infections caused by carbapenem-resistant Enterobacteriaceae (CRE). Despite improved... 
carbapenem-resistant Enterobacteriaceae | bacterial genomics | antimicrobial resistance | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | ceftazidime-avibactam | long-read sequencing | Klebsiella pneumoniae | ENTEROBACTERIACEAE
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 12/2017, Volume 61, Issue 12
Ceftolozane-tazobactam is a cephalosporin-beta-lactamase inhibitor combination that exhibits potent in vitro activity against Pseudomonas aeruginosa, including... 
AmpC | G183D | CEFTAZIDIME/AVIBACTAM | ceftolozane-tazobactam | Pseudomonas aeruginosa | MICROBIOLOGY | PHARMACOLOGY & PHARMACY
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2018, Volume 62, Issue 3
Ceftazidime-avibactam (CAZ-AVI) is a promising novel treatment for infections caused by carbapenem-resistant Enterobacteriaceae (CRE). Despite improved... 
Long-read sequencing | Carbapenem-resistant Enterobacteriaceae | Antimicrobial resistance | Bacterial genomics | Ceftazidime-avibactam | Klebsiella pneumoniae | Index Medicus
Journal Article
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, ISSN 0066-4804, 03/2017, Volume 61, Issue 3
Ceftazidime-avibactam is a novel beta lactam/ beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce... 
MORTALITY | VARIANTS | Klebsiella pneumoniae carbapenemase,sequence type 258 | SEQUENCE TYPE 258 | MICROBIOLOGY | ceftazidime-avibactam | resistance | carbapenem-resistant Enterobacteriaceae | EVOLUTION | THERAPY | BETA-LACTAMASE | BACTEREMIA | US HOSPITALS | PHARMACOLOGY & PHARMACY | Klebsiella pneumoniae | ENTEROBACTERIACEAE | KPC
Journal Article
Journal of Global Antimicrobial Resistance, ISSN 2213-7165, 07/2019
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.